{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:54:14Z","timestamp":1777870454205,"version":"3.51.4"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nephrol"],"DOI":"10.1007\/s40620-025-02334-1","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T09:37:29Z","timestamp":1752572249000},"page":"1655-1661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Potentially reversible severe cardiac involvement in thrombotic microangiopathies with malignant hypertension"],"prefix":"10.1093","volume":"38","author":[{"given":"Marco","family":"Allinovi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3904-6463","authenticated-orcid":false,"given":"Silvia","family":"Menale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Querin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"Caroti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Antognoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calogero Lino","family":"Cirami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niccol\u00f2","family":"Marchionni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Scheggi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"8","key":"2334_CR1","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1007\/s00467-018-3933-3","volume":"33","author":"K Fidan","year":"2018","unstructured":"Fidan K, G\u00f6knar N, G\u00fclhan B, Melek E, Y\u0131ld\u0131r\u0131m ZY, Bask\u0131n E et al (2018) Extra-renal manifestations of atypical hemolytic uremic syndrome in children. Pediatr Nephrol 33(8):1395\u20131403. https:\/\/doi.org\/10.1007\/s00467-018-3933-3","journal-title":"Pediatr Nephrol"},{"issue":"1","key":"2334_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030886","volume":"7","author":"F Dierkes","year":"2012","unstructured":"Dierkes F, Andriopoulos N, Sucker C, Kuhr K, Hollenbeck M, Hetzel GR et al (2012) Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. PLoS ONE 7(1):e30886. https:\/\/doi.org\/10.1371\/journal.pone.0030886","journal-title":"PLoS ONE"},{"issue":"2","key":"2334_CR3","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/HJH.0000000000001913","volume":"37","author":"S Rubin","year":"2019","unstructured":"Rubin S, Cremer A, Boulestreau R, Rigothier C, Kuntz S, Gosse P (2019) Malignant hypertension: diagnosis, treatment and prognosis with experience from the Bordeaux cohort. J Hypertens 37(2):316\u2013324. https:\/\/doi.org\/10.1097\/HJH.0000000000001913","journal-title":"J Hypertens"},{"issue":"8","key":"2334_CR4","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/jhh.2015.112","volume":"30","author":"A Cremer","year":"2016","unstructured":"Cremer A, Amraoui F, Lip GYH, Morales E, Rubin S, Segura J et al (2016) From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens 30(8):463\u2013466. https:\/\/doi.org\/10.1038\/jhh.2015.112","journal-title":"J Hum Hypertens"},{"issue":"2","key":"2334_CR5","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0163-7258(80)80021-0","volume":"9","author":"P Kincaid-Smith","year":"1980","unstructured":"Kincaid-Smith P (1980) Malignant hypertension: mechanisms and management. Pharmacol Ther 9(2):245\u2013269. https:\/\/doi.org\/10.1016\/S0163-7258(80)80021-0","journal-title":"Pharmacol Ther"},{"issue":"5","key":"2334_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cjca.2020.02.081","volume":"36","author":"RM Touyz","year":"2020","unstructured":"Touyz RM, Rios FJ, Alves-Lopes R, Neves KB, Camargo LL, Montezano AC (2020) Oxidative stress: a unifying paradigm in hypertension. Can J Cardiol 36(5):659\u2013670. https:\/\/doi.org\/10.1016\/j.cjca.2020.02.081","journal-title":"Can J Cardiol"},{"issue":"2","key":"2334_CR7","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5551\/jat.RV17026","volume":"26","author":"Y Yoshida","year":"2019","unstructured":"Yoshida Y, Kato H, Ikeda Y, Nangaku M (2019) Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb 26(2):99\u2013110. https:\/\/doi.org\/10.5551\/jat.RV17026","journal-title":"J Atheroscler Thromb"},{"issue":"4","key":"2334_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.kint.2019.05.014","volume":"96","author":"T Cavero","year":"2019","unstructured":"Cavero T, Arjona E, Soto K, Caravaca-Font\u00e1n F, Rabasco C, Bravo L et al (2019) Severe and malignant hypertension are common in primary atypical hemolytic uremic syndrome. Kidney Int 96(4):995\u20131004. https:\/\/doi.org\/10.1016\/j.kint.2019.05.014","journal-title":"Kidney Int"},{"issue":"12","key":"2334_CR9","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.3324\/haematol.2019.216903","volume":"104","author":"KK El","year":"2019","unstructured":"El KK, Boudhabhay I, Petitprez F, Vieira-Martins P, Fakhouri F, Zuber J et al (2019) Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome. Haematologica 104(12):2501\u20132511. https:\/\/doi.org\/10.3324\/haematol.2019.216903","journal-title":"Haematologica"},{"issue":"8","key":"2334_CR10","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41581-021-00424-4","volume":"17","author":"F Fakhouri","year":"2021","unstructured":"Fakhouri F, Fr\u00e9meaux-Bacchi V (2021) Thrombotic microangiopathy in aHUS and beyond: clinical clues from complement genetics. Nat Rev Nephrol 17(8):543\u2013553. https:\/\/doi.org\/10.1038\/s41581-021-00424-4","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"2334_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s40620-022-01465-z","volume":"36","author":"JM Halimi","year":"2023","unstructured":"Halimi JM, Al-Dakkak I, Anokhina K, Ardissino G, Licht C, Lim WH et al (2023) Clinical characteristics and outcomes of a patient population with atypical hemolytic uremic syndrome and malignant hypertension: analysis from the Global aHUS registry. J Nephrol 36(3):817\u2013828. https:\/\/doi.org\/10.1007\/s40620-022-01465-z","journal-title":"J Nephrol"},{"issue":"9","key":"2334_CR12","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1007\/s40620-023-01644-6","volume":"36","author":"X Chen","year":"2023","unstructured":"Chen X, Zhang X, Wang Y, Wang S, Zhao M (2023) Genetic, clinical, and pathological study of patients with severe hypertension-associated renal microangiopathy. J Nephrol 36(9):2477\u20132490. https:\/\/doi.org\/10.1007\/s40620-023-01644-6","journal-title":"J Nephrol"},{"issue":"7","key":"2334_CR13","doi-asserted-by":"publisher","first-page":"834","DOI":"10.5858\/2003-127-834-TTPAHU","volume":"127","author":"GA Hosler","year":"2003","unstructured":"Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities a review of 56 autopsy cases. Arch Pathol Lab Med 127(7):834\u2013839. https:\/\/doi.org\/10.5858\/2003-127-834-TTPAHU","journal-title":"Arch Pathol Lab Med"},{"issue":"17","key":"2334_CR14","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1016\/j.jacc.2024.02.037","volume":"83","author":"R Boulestreau","year":"2024","unstructured":"Boulestreau R, \u015apiewak M, Januszewicz A, Kreutz R, Guzik TJ, Januszewicz M et al (2024) Malignant hypertension: a systemic cardiovascular disease: JACC review topic of the week. J Am Coll Cardiol 83(17):1688\u20131701. https:\/\/doi.org\/10.1016\/j.jacc.2024.02.037","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"2334_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1046\/j.1523-1755.2001.060003831.x","volume":"60","author":"P Ruggenenti","year":"2001","unstructured":"Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60(3):831\u2013846. https:\/\/doi.org\/10.1046\/j.1523-1755.2001.060003831.x","journal-title":"Kidney Int"},{"issue":"12","key":"2334_CR16","doi-asserted-by":"publisher","first-page":"254","DOI":"10.4330\/wjc.v10.i12.254","volume":"10","author":"SL Wiernek","year":"2018","unstructured":"Wiernek SL, Jiang B, Gustafson GM, Dai X (2018) Cardiac implications of thrombotic thrombocytopenic purpura. World J Cardiol 10(12):254\u2013266. https:\/\/doi.org\/10.4330\/wjc.v10.i12.254","journal-title":"World J Cardiol"},{"issue":"10","key":"2334_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030431","volume":"3","author":"JP Venables","year":"2006","unstructured":"Venables JP, Strain L, Routledge D, Bourn D, Powell HM, Warwicker P et al (2006) Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 3(10):e431. https:\/\/doi.org\/10.1371\/journal.pmed.0030431","journal-title":"PLoS Med"},{"issue":"6","key":"2334_CR18","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1093\/ndt\/gfq160","volume":"25","author":"M Sall\u00e9e","year":"2010","unstructured":"Sall\u00e9e M, Daniel L, Piercecchi MD, Jaubert D, Fremeaux-Bacchi V, Berland Y et al (2010) Myocardial infarction is a complication of factor H-associated atypical HUS. Nephrol Dial Transplant 25(6):2028\u20132032. https:\/\/doi.org\/10.1093\/ndt\/gfq160","journal-title":"Nephrol Dial Transplant"},{"issue":"12","key":"2334_CR19","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1007\/s00431-016-2790-y","volume":"175","author":"D Rigamonti","year":"2016","unstructured":"Rigamonti D, Simonetti GD (2016) Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr 175(12):1927\u20131931. https:\/\/doi.org\/10.1007\/s00431-016-2790-y","journal-title":"Eur J Pediatr"},{"issue":"6","key":"2334_CR20","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1093\/ndt\/gfl127","volume":"21","author":"D Patschan","year":"2006","unstructured":"Patschan D, Witzke O, D\u00fchrsen U, Erbel R, Philipp T, Herget-Rosenthal S (2006) Acute myocardial infarction in thrombotic microangiopathies\u2014clinical characteristics, risk factors and outcome. Nephrol Dial Transplant 21(6):1549\u20131554. https:\/\/doi.org\/10.1093\/ndt\/gfl127","journal-title":"Nephrol Dial Transplant"},{"key":"2334_CR21","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/327980","volume":"2015","author":"JL Vaughn","year":"2015","unstructured":"Vaughn JL, Moore JM, Cataland SR (2015) Acute systolic heart failure associated with complement-mediated hemolytic uremic syndrome. Case Rep Hematol 2015:327980. https:\/\/doi.org\/10.1155\/2015\/327980","journal-title":"Case Rep Hematol"},{"key":"2334_CR22","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.jpeds.2021.03.067","volume":"235","author":"E Sanders","year":"2021","unstructured":"Sanders E, Brown CC, Blaszak RT, Crawford B, Prodhan P (2021) Cardiac manifestation among children with hemolytic uremic syndrome. J Pediatr 235:144-148.e4. https:\/\/doi.org\/10.1016\/j.jpeds.2021.03.067","journal-title":"J Pediatr"},{"issue":"5","key":"2334_CR23","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.amjmed.2005.02.019","volume":"118","author":"AS Gami","year":"2005","unstructured":"Gami AS, Hayman SR, Grande JP, Garovic VD (2005) Incidence and prognosis of acute heart failure in the thrombotic microangiopathies. Am J Med 118(5):544\u2013547. https:\/\/doi.org\/10.1016\/j.amjmed.2005.02.019","journal-title":"Am J Med"},{"issue":"3","key":"2334_CR24","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/nrneph.2013.280","volume":"10","author":"M Noris","year":"2014","unstructured":"Noris M, Remuzzi G (2014) Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol 10(3):174\u2013180. https:\/\/doi.org\/10.1038\/nrneph.2013.280","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2334_CR25","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1537-2995.2007.01534.x","volume":"48","author":"BM Hawkins","year":"2008","unstructured":"Hawkins BM, Abu-Fadel M, Vesely SK, George JN (2008) Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review. Transfusion (Paris) 48(2):382\u2013392. https:\/\/doi.org\/10.1111\/j.1537-2995.2007.01534.x","journal-title":"Transfusion (Paris)"},{"issue":"1","key":"2334_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s00246-004-0708-3","volume":"26","author":"NJ Thomas","year":"2005","unstructured":"Thomas NJ, Messina JJ, Debruin WJ, Carcillo JA (2005) Cardiac failure in hemolytic uremic syndrome and rescue with extracorporeal life support. Pediatr Cardiol 26(1):104\u2013106. https:\/\/doi.org\/10.1007\/s00246-004-0708-3","journal-title":"Pediatr Cardiol"},{"issue":"19","key":"2334_CR27","doi-asserted-by":"publisher","first-page":"4261","DOI":"10.1182\/blood-2009-05-223834","volume":"114","author":"C Abarrategui-Garrido","year":"2009","unstructured":"Abarrategui-Garrido C, Mart\u00ednez-Barricarte R, L\u00f3pez-Trascasa M, Rodr\u00edguez De C\u00f3rdoba S, S\u00e1nchez-Corral P (2009) Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114(19):4261\u20134271. https:\/\/doi.org\/10.1182\/blood-2009-05-223834","journal-title":"Blood"},{"issue":"12","key":"2334_CR28","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1681\/ASN.2010030315","volume":"21","author":"MA Dragon-Durey","year":"2010","unstructured":"Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B et al (2010) Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 21(12):2180\u20132187. https:\/\/doi.org\/10.1681\/ASN.2010030315","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"2334_CR29","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/nejmoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C et al (2013) Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 368(23):2169\u20132181. https:\/\/doi.org\/10.1056\/nejmoa1208981","journal-title":"N Engl J Med"},{"issue":"12","key":"2334_CR30","doi-asserted-by":"publisher","first-page":"2323","DOI":"10.1007\/s00467-012-2276-8","volume":"27","author":"R Vilalta","year":"2012","unstructured":"Vilalta R, Lara E, Madrid A, Chocron S, Mu\u00f1oz M, Casquero A et al (2012) Long-term eculizumab improves clinical outcomes in atypical hemolytic uremic syndrome. Pediatr Nephrol 27(12):2323\u20132326. https:\/\/doi.org\/10.1007\/s00467-012-2276-8","journal-title":"Pediatr Nephrol"},{"key":"2334_CR31","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/275825","volume":"2015","author":"N De Schryver","year":"2015","unstructured":"De Schryver N, Hoton D, Castanares-Zapatero D, Hantson P (2015) Acute ventricular wall thickening: sepsis, thrombotic microangiopathy, or myocarditis? Case Rep Cardiol 2015:275825. https:\/\/doi.org\/10.1155\/2015\/275825","journal-title":"Case Rep Cardiol"},{"key":"2334_CR32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2369-14-3","volume":"14","author":"M Sall\u00e9e","year":"2013","unstructured":"Sall\u00e9e M, Ismail K, Fakhouri F, Vacher-Coponat H, Moussi-Franc\u00e9s J, Fr\u00e9maux-Bacchi V et al (2013) Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol 14:3. https:\/\/doi.org\/10.1186\/1471-2369-14-3","journal-title":"BMC Nephrol"},{"issue":"3","key":"2334_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1177\/2040620715571076","volume":"6","author":"N Khanal","year":"2015","unstructured":"Khanal N, Upadhyay S, Dahal S, Bhatt VR, Bierman PJ (2015) Differentiating malignant hypertension-induced thrombotic microangiopathy from thrombotic thrombocytopenic purpura. Ther Adv Hematol 6(3):97\u2013102. https:\/\/doi.org\/10.1177\/2040620715571076","journal-title":"Ther Adv Hematol"},{"issue":"8","key":"2334_CR34","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1111\/jth.13032","volume":"13","author":"A Maino","year":"2015","unstructured":"Maino A, Siegerink B, Lotta LA, Crawley JTB, le Cessie S, Leebeek FWG et al (2015) Plasma ADAMTS-13 levels and the risk of myocardial infarction: an individual patient data meta-analysis. J Thromb Haemost 13(8):1396\u20131404. https:\/\/doi.org\/10.1111\/jth.13032","journal-title":"J Thromb Haemost"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-025-02334-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-025-02334-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:59:32Z","timestamp":1777564772000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/38\/6\/1655\/8457520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":34,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2334"],"URL":"https:\/\/doi.org\/10.1007\/s40620-025-02334-1","relation":{},"ISSN":["1724-6059"],"issn-type":[{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"15 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Approval was obtained from the local ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"At admission, the patient signed a generic informed consent form for the treatment of personal data and publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent to participate"}}]}}